{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:01:41Z","timestamp":1790845301028,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying treatable traits in critically ill patients offers potential to enable a precision medicine approach to treatment. The aim of this exploratory analysis of the REMAP-CAP immune modulation domain was to evaluate whether plasma ferritin or soluble urokinase plasminogen activator receptor (suPAR) represent treatable traits for anakinra in critically ill patients with coronavirus disease (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An exploratory analysis of patients randomised within the COVID-19 immune modulation domain of the REMAP-CAP trial was conducted. Adults within 24\u00a0h of receiving respiratory or cardiovascular organ support in an ICU with suspected or microbiologically confirmed COVID-19 were included. Plasma ferritin was measured at study sites, and plasma suPAR measured in stored plasma samples. The primary outcome was organ support-free days (OSFD) until day 21. Analyses were performed using a Bayesian cumulative logistic regression model, and results are presented as the posterior median odds ratio (OR), along with 95% credible intervals (CrI), for anakinra being superior to control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In ferritin analyses, 1243 patients were included. Patients with increasing ferritin levels had numerically fewer OSFDs. The posterior probabilities of anakinra having benefit (OR\u2009&gt;\u20091) were 64%, 71%, and 21% across increasing ferritin terciles, compared to 53% in analyses that did not adjust for ferritin levels. 145 patients were included in the suPAR analyses. Patients with high baseline plasma suPAR (\u2265\u20096 ng\/ml;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200985) had numerically fewer OSFDs than patients with low plasma suPAR (-1.0 (-1.0, 9.0) vs. 13.0 (-1.0, 17.0)). The posterior probabilities of anakinra having benefit (OR\u2009&gt;\u20091) were 94.8% (OR 2.28 [0.85\u20136.06]) in patients with low baseline suPAR, and 38.6% (OR 0.88 [0.39\u20132.00]) in patients with high baseline suPAR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma ferritin does not identify patients with COVID-19 who benefit from treatment with anakinra, whilst anakinra may be beneficial in patients with low, rather than high, baseline plasma suPAR. These hypothesis-generating findings contrast with the results of clinical trials in non-critically ill patients with COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT02735707. Date of trial registration: 06\/04\/2016<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-026-06311-3","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:36:25Z","timestamp":1790843785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-805X","authenticated-orcid":false,"given":"Andrew J.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennie","family":"Derde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Shankar-Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank van de","family":"Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the REMAP-CAP Immune Modulation Domain Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"6311_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","volume":"28","author":"DM Maslove","year":"2022","unstructured":"Maslove DM, Tang B, Shankar-Hari M, Lawler PR, Angus DC, Baillie JK, et al. Redefining critical illness. Nat Med Nat Publishing Group. 2022;28:1141\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01843-x.","journal-title":"Nat Med Nat Publishing Group"},{"key":"6311_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611\u201320. https:\/\/doi.org\/10.1016\/S2213-2600(14)70097-9.","journal-title":"Lancet Respir Med"},{"key":"6311_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691\u20138. https:\/\/doi.org\/10.1016\/S2213-2600(18)30177-2.","journal-title":"Lancet Respir Med"},{"key":"6311_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13054-022-04025-w","volume":"26","author":"AJ Boyle","year":"2022","unstructured":"Boyle AJ, Ferris P, Bradbury I, Conlon J, Shankar-Hari M, Rogers AJ, et al. Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. Crit Care. 2022;26:164. https:\/\/doi.org\/10.1186\/s13054-022-04025-w.","journal-title":"Crit Care"},{"key":"6311_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial. Am J Respir Crit Care Med Am Thorac Soc - AJRCCM. 2019;199:980\u20136. https:\/\/doi.org\/10.1164\/rccm.201807-1419OC.","journal-title":"Am J Respir Crit Care Med Am Thorac Soc - AJRCCM"},{"key":"6311_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/thorax-2023-220538","volume":"79","author":"DB Antcliffe","year":"2024","unstructured":"Antcliffe DB, Mi Y, Santhakumaran S, Burnham KL, Prevost AT, Ward JK, et al. Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes. Thorax BMJ Publishing Group Ltd. 2024;79:515\u201323. https:\/\/doi.org\/10.1136\/thorax-2023-220538.","journal-title":"Thorax BMJ Publishing Group Ltd"},{"key":"6311_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00134-022-06869-w","volume":"48","author":"M Fish","year":"2022","unstructured":"Fish M, Rynne J, Jennings A, Lam C, Lamikanra AA, Ratcliff J, et al. Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. Intensive Care Med. 2022;48:1525\u201338. https:\/\/doi.org\/10.1007\/s00134-022-06869-w.","journal-title":"Intensive Care Med"},{"key":"6311_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00134-024-07733-9","volume":"51","author":"J Rynne","year":"2025","unstructured":"Rynne J, Mosavie M, Masse M-H, M\u00e9nard J, Battista M-C, Maslove DM, et al. Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial. Intensive Care Med. 2025;51:82\u201393. https:\/\/doi.org\/10.1007\/s00134-024-07733-9.","journal-title":"Intensive Care Med"},{"key":"6311_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/eme08100","volume":"8","author":"M Shankar-Hari","year":"2021","unstructured":"Shankar-Hari M, Santhakumaran S, Prevost AT, Prevost A, Ward JK, Ward J, et al. Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. Effic Mech Eval. 2021;8:1\u2013104. https:\/\/doi.org\/10.3310\/eme08100.","journal-title":"Effic Mech Eval"},{"key":"6311_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/thorax-2024-222488","volume":"80","author":"L Derde","year":"2025","unstructured":"Derde L, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax BMJ Publishing Group Ltd. 2025;80:530\u20139. https:\/\/doi.org\/10.1136\/thorax-2024-222488.","journal-title":"Thorax BMJ Publishing Group Ltd"},{"key":"6311_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*. Crit Care Med. 2016;44:275\u201381. https:\/\/doi.org\/10.1097\/CCM.0000000000001402.","journal-title":"Crit Care Med"},{"key":"6311_CR12","doi-asserted-by":"publisher","unstructured":"Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, Efthymiou A, Koutsoukou V, Ehler J, et al. Precision immunotherapy to improve sepsis outcomes: the ImmunoSep randomized clinical trial. JAMA [Internet]. 2025 Dec 8 [cited 2025 Dec 12]. https:\/\/doi.org\/10.1001\/jama.2025.24175.","DOI":"10.1001\/jama.2025.24175"},{"key":"6311_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/thorax-2023-220292","volume":"79","author":"P Mehta","year":"2024","unstructured":"Mehta P, Samanta RJ, Wick K, Coll RC, Mawhinney T, McAleavey PG, et al. Elevated ferritin, mediated by IL-18 is associated with systemic inflammation and mortality in acute respiratory distress syndrome (ARDS). Thorax. BMJ Publishing Group Ltd. 2024;79:227\u201335. https:\/\/doi.org\/10.1136\/thorax-2023-220292.","journal-title":"BMJ Publishing Group Ltd"},{"key":"6311_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13054-020-03166-0","volume":"24","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care. 2020;24:445. https:\/\/doi.org\/10.1186\/s13054-020-03166-0.","journal-title":"Crit Care"},{"key":"6311_CR15","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med Nat Publishing Group. 2021;27:1752\u201360. https:\/\/doi.org\/10.1038\/s41591-021-01499-z.","journal-title":"Nat Med Nat Publishing Group"},{"key":"6311_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa1911481","volume":"382","author":"SS Hayek","year":"2020","unstructured":"Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, et al. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020;382:416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1911481.","journal-title":"N Engl J Med"},{"key":"6311_CR17","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.3892\/etm.2019.7931","volume":"18","author":"D Chen","year":"2019","unstructured":"Chen D, Wu X, Yang J, Yu L. Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality. Exp Ther Med. 2019;18:2984\u201392. https:\/\/doi.org\/10.3892\/etm.2019.7931.","journal-title":"Exp Ther Med"},{"key":"6311_CR18","doi-asserted-by":"publisher","unstructured":"The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19: the REMAP-CAP COVID-19 Immune Modulation Therapy Domain randomized clinical trial [Internet]. medRxiv; 2021 [cited 2024 Jun 25]. p. 2021.06.18.21259133. https:\/\/doi.org\/10.1101\/2021.06.18.21259133.","DOI":"10.1101\/2021.06.18.21259133"},{"key":"6311_CR19","doi-asserted-by":"publisher","unstructured":"Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study: rationale and design. Ann Am Thorac Soc [Internet]. 2020 Jul [cited 2025 Aug 14]. https:\/\/doi.org\/10.1513\/AnnalsATS.202003-192SD.","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"key":"6311_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/17407745221112013","volume":"19","author":"BR Saville","year":"2022","unstructured":"Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. Clin Trials SAGE Publications. 2022;19:490\u2013501. https:\/\/doi.org\/10.1177\/17407745221112013.","journal-title":"Clin Trials SAGE Publications"},{"key":"6311_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","volume":"24","author":"N Rovina","year":"2020","unstructured":"Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020;24:187. https:\/\/doi.org\/10.1186\/s13054-020-02897-4.","journal-title":"Crit Care"},{"key":"6311_CR22","doi-asserted-by":"publisher","unstructured":"Brands X, de Vries FMC, Uhel F, Haak BW, Peters-Sengers H, Schuurman AR, et al. Plasma ferritin as marker of macrophage activation-like syndrome in critically ill patients with community-acquired pneumonia. Crit Care Med [Internet]. 2021 Nov 1 [cited 2021 May 10]; Latest Articles. https:\/\/doi.org\/10.1097\/CCM.0000000000005072.","DOI":"10.1097\/CCM.0000000000005072"},{"key":"6311_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","volume":"9","author":"J Declercq","year":"2021","unstructured":"Declercq J, Damme KFAV, Leeuw ED, Maes B, Bosteels C, Tavernier SJ, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med Elsevier. 2021;9:1427\u201338. https:\/\/doi.org\/10.1016\/S2213-2600(21)00377-5.","journal-title":"Lancet Respir Med Elsevier"},{"key":"6311_CR24","doi-asserted-by":"publisher","unstructured":"Reddy K, Sinha P, Antcliffe DB, McDowell C, Bradley PA, Black L, et al. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study. Lancet Respir Med [Internet]. 2026 Mar 23 [cited 2026 Mar 24]. https:\/\/doi.org\/10.1016\/S2213-2600(26)00040-8.","DOI":"10.1016\/S2213-2600(26)00040-8"},{"key":"6311_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/172460080101600402","volume":"16","author":"R Riisbro","year":"2001","unstructured":"Riisbro R, Christensen IJ, H\u00f8gdall C, Br\u00fcnner N, H\u00f8gdall E. Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling. Int J Biol Markers SAGE Publications Ltd STM. 2001;16:233\u20139. https:\/\/doi.org\/10.1177\/172460080101600402.","journal-title":"Int J Biol Markers SAGE Publications Ltd STM"},{"key":"6311_CR26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00134-015-3924-9","volume":"41","author":"DGPJ Geboers","year":"2015","unstructured":"Geboers DGPJ, de Beer FM, Boer AMT, van der Poll T, Horn J, Cremer OL, et al. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med. 2015;41:1281\u201390. https:\/\/doi.org\/10.1007\/s00134-015-3924-9.","journal-title":"Intensive Care Med"},{"key":"6311_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00134-012-2730-x","volume":"39","author":"V Jalkanen","year":"2013","unstructured":"Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, et al. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med. 2013;39:489\u201396. https:\/\/doi.org\/10.1007\/s00134-012-2730-x.","journal-title":"Intensive Care Med"},{"key":"6311_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40560-019-0381-5","volume":"7","author":"H Gussen","year":"2019","unstructured":"Gussen H, Hohlstein P, Bartneck M, Warzecha KT, Buendgens L, Luedde T, et al. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. J Intensive Care. 2019;7:26. https:\/\/doi.org\/10.1186\/s40560-019-0381-5.","journal-title":"J Intensive Care"},{"key":"6311_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12882-023-03255-6","volume":"24","author":"SW Majoni","year":"2023","unstructured":"Majoni SW, Nelson J, Graham J, Abeyaratne A, Fernandes DK, Cherian S, et al. Comparison of two ferritin assay platforms to assess their level of agreement in measuring serum and plasma ferritin levels in patients with chronic kidney disease. BMC Nephrol. 2023;24:198. https:\/\/doi.org\/10.1186\/s12882-023-03255-6.","journal-title":"BMC Nephrol"},{"key":"6311_CR30","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/clinchem\/hvac099","volume":"68","author":"F Braga","year":"2022","unstructured":"Braga F, Pasqualetti S, Frusciante E, Borrillo F, Chibireva M, Panteghini M. Harmonization Status of Serum Ferritin Measurements and Implications for Use as Marker of Iron-Related Disorders. Clin Chem. 2022;68:1202\u201310. https:\/\/doi.org\/10.1093\/clinchem\/hvac099.","journal-title":"Clin Chem"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06311-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:36:26Z","timestamp":1790843786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6311"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06311-3","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The REMAP-CAP immune modulation domain involved human participants and all procedures were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by all relevant national or local ethics committees. Participants gave informed consent to participate in the study before taking part.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB: Supported by an NIHR Efficacy and Mechanism Evaluation Advanced Fellowship (NIHR 168885), reports grants from the Irish Critical Care Clinical Trials Group and has received in-kind support from Virogates to measure plasma suPAR outside the submitted work. LRB: Employed by Berry Consultants, which receives payments for statistical modelling and design of REMAP-CAP. LD: reports grants from ECRAID-Base (HORIZON-Health (2021-2026) Grant agreement ID: 965313DFM reports grants from the NIHR, the MRC, the Northern Ireland HSC R&D Division, the Wellcome Trust, Innovate UK, Novavax and Randox Laboratories outside the submitted work. He reports consulting fees from Bayer, Aptarion, Direct Biologics, Healios, Novartis, and MSD outside the submitted work. He reports a patent for a novel treatment for inflammatory disease (USB962032), issued to his institution outside the submitted work. He also reports his role as the Scientific Director for Research Programmes for the NIHR.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"506"}}